Sea Mild Biotechnology Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 4/6
Sea Mild Biotechnology has a total shareholder equity of NT$86.2M and total debt of NT$53.3M, which brings its debt-to-equity ratio to 61.9%. Its total assets and total liabilities are NT$243.6M and NT$157.4M respectively. Sea Mild Biotechnology's EBIT is NT$11.5M making its interest coverage ratio 14.3. It has cash and short-term investments of NT$63.4M.
Wichtige Informationen
61.9%
Verhältnis von Schulden zu Eigenkapital
NT$53.33m
Verschuldung
| Zinsdeckungsgrad | 14.3x |
| Bargeld | NT$63.42m |
| Eigenkapital | NT$86.21m |
| Gesamtverbindlichkeiten | NT$157.39m |
| Gesamtvermögen | NT$243.59m |
Jüngste Berichte zur Finanzlage
Keine Aktualisierungen
Recent updates
Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: 7516's short term assets (NT$195.9M) exceed its short term liabilities (NT$155.0M).
Langfristige Verbindlichkeiten: 7516's short term assets (NT$195.9M) exceed its long term liabilities (NT$2.4M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: 7516 has more cash than its total debt.
Schulden abbauen: 7516's debt to equity ratio has increased from 1.9% to 61.9% over the past 5 years.
Schuldendeckung: 7516's operating cash flow is negative, therefore debt is not well covered.
Zinsdeckung: 7516's interest payments on its debt are well covered by EBIT (14.3x coverage).